drugset / Trial / NCT01704599

Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

NCT01704599

Phase 1/2 Terminated 8 enrolled Wayne State University Abbott · collab
NaSingle-groupOpen-labelTreatment

Summary

Vitamins modulating homocysteine affect both TNF-alpha, vascular endothelial growth factor, and theoretically enhance the anti-inflammatory version of NOS thus hopefully increasing the efficacy and reducing the chance of some toxicities of adalimumab as determined by blood testing and EKGs.

Timeline

Start
2009-01
Primary completion
2013-06
Completion
2014-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pyridoxine Unknown 100 mg Oral
Subject Vitamin B12 Other / unclassified 1000 ug Oral
Subject folic acid Other / unclassified 5 mg Oral
Background Adalimumab Monoclonal antibody

Indications